vTv Therapeutics (VTVT) Cash & Equivalents (2014 - 2026)

vTv Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $98.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 215.81% year-over-year to $98.1 million; the TTM figure through Mar 2026 stood at $98.1 million (up 215.81% YoY), while the FY2025 annual figure was $88.9 million, up 142.02% from the prior year.
• Cash & Equivalents came in at $98.1 million for Q1 2026 at vTv Therapeutics, up from $88.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.5 million in Q3 2025 to a low of $8.2 million in Q3 2023.
• A 5-year average of $36.8 million and a median of $25.9 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 46.54% in 2023 and surged 406.96% in 2024, its largest moves.
• vTv Therapeutics' Cash & Equivalents stood at $12.1 million in 2022, then dropped by 22.1% to $9.4 million in 2023, then surged by 289.01% to $36.7 million in 2024, then surged by 142.02% to $88.9 million in 2025, then rose by 10.29% to $98.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $98.1 million, $88.9 million, and $98.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison